TY  - JOUR
AU  - Bajić, Vladan
AU  - Mandusić, Vesna
AU  - Stefanova, Elka
AU  - Bozović, Ana
AU  - Davidović, Radoslav
AU  - Živković, Lada
AU  - Pirković, Andrea
AU  - Potparević, Biljana
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2386
AB  - X-chromosome instability has been a long established feature in Alzheimer's disease ( AD). Premature centromere division and aneuploidy of the X-chromosome has been found in peripheral blood lymphocytes and neuronal tissue in female AD patients. Interestingly, only one chromosome of the X pair has been affected. These results raised a question, "Is the X-chromosome inactivation pattern altered in peripheral blood lymphocytes ofwomen affected by AD?" To address this question, we analyzed the methylation status of androgen receptor promoter which may show us any deviation from the 50 : 50% X inactivation status in peripheral blood lymphocytes ofwomen with AD. Our results showed skewed inactivation patterns (>90%). These findings suggest that an epigenetic alteration on the inactivation centers of the X-chromosome (or skewing) relates not only to aging, by might be a novel property that could account for the higher incidence of AD in women.
PB  - Ios Press, Amsterdam
T2  - Journal of Alzheimers Disease
T1  - Skewed X-Chromosome Inactivation in Women Affected by Alzheimer's Disease
VL  - 43
IS  - 4
SP  - 1251
EP  - 1259
DO  - 10.3233/JAD-141674
ER  - 

@article{
author = "Bajić, Vladan and Mandusić, Vesna and Stefanova, Elka and Bozović, Ana and Davidović, Radoslav and Živković, Lada and Pirković, Andrea and Potparević, Biljana",
year = "2015",
abstract = "X-chromosome instability has been a long established feature in Alzheimer's disease ( AD). Premature centromere division and aneuploidy of the X-chromosome has been found in peripheral blood lymphocytes and neuronal tissue in female AD patients. Interestingly, only one chromosome of the X pair has been affected. These results raised a question, "Is the X-chromosome inactivation pattern altered in peripheral blood lymphocytes ofwomen affected by AD?" To address this question, we analyzed the methylation status of androgen receptor promoter which may show us any deviation from the 50 : 50% X inactivation status in peripheral blood lymphocytes ofwomen with AD. Our results showed skewed inactivation patterns (>90%). These findings suggest that an epigenetic alteration on the inactivation centers of the X-chromosome (or skewing) relates not only to aging, by might be a novel property that could account for the higher incidence of AD in women.",
publisher = "Ios Press, Amsterdam",
journal = "Journal of Alzheimers Disease",
title = "Skewed X-Chromosome Inactivation in Women Affected by Alzheimer's Disease",
volume = "43",
number = "4",
pages = "1251-1259",
doi = "10.3233/JAD-141674"
}

Bajić, V., Mandusić, V., Stefanova, E., Bozović, A., Davidović, R., Živković, L., Pirković, A.,& Potparević, B.. (2015). Skewed X-Chromosome Inactivation in Women Affected by Alzheimer's Disease. in Journal of Alzheimers Disease
Ios Press, Amsterdam., 43(4), 1251-1259.
https://doi.org/10.3233/JAD-141674

Bajić V, Mandusić V, Stefanova E, Bozović A, Davidović R, Živković L, Pirković A, Potparević B. Skewed X-Chromosome Inactivation in Women Affected by Alzheimer's Disease. in Journal of Alzheimers Disease. 2015;43(4):1251-1259.
doi:10.3233/JAD-141674 .

Bajić, Vladan, Mandusić, Vesna, Stefanova, Elka, Bozović, Ana, Davidović, Radoslav, Živković, Lada, Pirković, Andrea, Potparević, Biljana, "Skewed X-Chromosome Inactivation in Women Affected by Alzheimer's Disease" in Journal of Alzheimers Disease, 43, no. 4 (2015):1251-1259,
https://doi.org/10.3233/JAD-141674 . .

TY  - JOUR
AU  - Kostić, Vladimir
AU  - Džoljić, Eleonora
AU  - Todorović, Zoran
AU  - Mijajlović, Milija
AU  - Svetel, Marina
AU  - Stefanova, Elka
AU  - Dragašević, Nataša
AU  - Petrović, Igor
AU  - Milošević, Milenko
AU  - Kovačević, Ivan
AU  - Miljković, Branislava
AU  - Pokrajac, Milena
AU  - Prostran, Milica
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1825
AB  - Background/Aim. Selective serotonin reuptake inhibitors are the most commonly chosen antidepressants in patients with Parkinson's disease (PD). The aim of our study was to assess the influence of fluoxetine (Flu) on motor functions in patients with PD. Methods. In this prospective, controlled, open-label study, 18 patients with PD and mild depression [(10 ≤ Hamilton Rating Scale for Depression (HDRS) ≤ 23)] without dementia [(25 ≤ Mini-Mental State Examination (MMSE)] were treated with Flu. Both single and repeated dose effects of Flu were assessed on days 1-80. Plasma concentrations of Flu and norfluoxetine (NORFlu) were correlated with the results of selected motor function performance scores: The Unified Parkinsons Disease Rating Score (UPDRS), Finger Tapping Test (FTT) and Purdue Pegboard Test (PPT). Severity of PD, depression and dementia were evaluated using standard tests [(Hoehn and Yahr stages (HY), activity of daily living (ADL), UPDRS, HDRS, MMSE)]. Results. Steady-state for Flu/NORFlu was reached after 18 days of treatment. Such a plateau correlated with significant improvements in both scores of depression and Parkinson's disability (HDRS, UPDRS and ADL, respectively). In addition, FTT and PPT scores also increased until day 18, with further slight fluctuations around the plateau. Optimal motor performances correlated with Flu concentrations of approximately 60-110 μg/L. Conclusion. Flu (20 mg/day) significantly reduced depression in PD patients while it did not impair their motor performances. Because substantial placebo effects may arise in studies of PD and depression, large, prospective, randomized, placebo-controlled clinical trials are warranted.
AB  - Uvod/Cilj. Selektivni inhibitori ponovnog preuzimanja serotonina su antidepresivi koji se najčešće koriste u lečenju obolelih od Parkinsonove bolesti (PB). Cilj ovog istraživanja bio je da se proceni uticaj fluoksetina (Flu) na motorne funkcije bolesnika sa PB. Metode. U ovom prospektivnom, kontrolisanom, otvorenom kliničkom ispitivanju, 18 bolesnika sa PB i blagom depresijom [10 ≤ Hamiltonova skala za depresiju (10 ≤ HDRS) ≤ 23)], bez demencije [(25 ≤ Mini mental test (MMSE)] lečeni su primenom Flu. Procenjivana su dejstva kako pojedinačne, tako i ponovljene doze Flu od prvog do osamdesetog dana. Plazma koncentracije Flu i norfluoksetina (NORFlu) korelisane su sa rezultatima odeđenih testova za motorne funkcije: skala za procenu težine PB (UPDRS), test spretnosti kucanja (FTT) i Purdue pegboard Test PPT). Izraženost PD, depresije i demencije procenjivane su korišćenjem standardnih testova [(test dnevnih aktivnosti (ADL), Hoehn.-Yahr. stadijumi (HJ), HDRS, MMSE)]. Rezultati. Ravnotežno stanje za Flu/NORFlu postignuto je 18. dana lečenja. Takav plato u koncentraciji Flu/NORFlu bio je praćen značajnim poboljšanjem rezultata, kako testova za depresiju, tako i za izraženost PB (HDRS, UPDRS i ADL, sledstveno). Dodatno, rezultati FTT-a i PPT-a bili su u porastu do 18. dana, sa blagim fluktuacijama oko platoa. Optimalna motorna postignuća zabeležena su pri koncentraciji Flu od oko 60-110 μg/L. Zaključak. Flu (20 mg/dan) značajno redukuje depresiju kod bolesnika sa PB i ne remeti motorne funkcije. S obzirom na mogući placebo efekat u istraživanjima sa PB i depresijom, neophodna su obimnija, prospektivna, randomizovana, placebo- kontrolisana klinička ispitivanja.
PB  - Vojnomedicinska akademija - Institut za naučne informacije, Beograd
T2  - Vojnosanitetski pregled
T1  - Fluoxetine does not impair motor function in patients with Parkinson's disease: Correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine
T1  - Fluoksetin ne remeti motornu funkciju kod bolesnika sa Parkinsonovom bolešću - korelacija raspoloženja i motorne funkcije sa koncentracijom fluoksetina/norfluoksetina u plazmi
VL  - 69
IS  - 12
SP  - 1067
EP  - 1075
DO  - 10.2298/VSP111114028K
ER  - 

@article{
author = "Kostić, Vladimir and Džoljić, Eleonora and Todorović, Zoran and Mijajlović, Milija and Svetel, Marina and Stefanova, Elka and Dragašević, Nataša and Petrović, Igor and Milošević, Milenko and Kovačević, Ivan and Miljković, Branislava and Pokrajac, Milena and Prostran, Milica",
year = "2012",
abstract = "Background/Aim. Selective serotonin reuptake inhibitors are the most commonly chosen antidepressants in patients with Parkinson's disease (PD). The aim of our study was to assess the influence of fluoxetine (Flu) on motor functions in patients with PD. Methods. In this prospective, controlled, open-label study, 18 patients with PD and mild depression [(10 ≤ Hamilton Rating Scale for Depression (HDRS) ≤ 23)] without dementia [(25 ≤ Mini-Mental State Examination (MMSE)] were treated with Flu. Both single and repeated dose effects of Flu were assessed on days 1-80. Plasma concentrations of Flu and norfluoxetine (NORFlu) were correlated with the results of selected motor function performance scores: The Unified Parkinsons Disease Rating Score (UPDRS), Finger Tapping Test (FTT) and Purdue Pegboard Test (PPT). Severity of PD, depression and dementia were evaluated using standard tests [(Hoehn and Yahr stages (HY), activity of daily living (ADL), UPDRS, HDRS, MMSE)]. Results. Steady-state for Flu/NORFlu was reached after 18 days of treatment. Such a plateau correlated with significant improvements in both scores of depression and Parkinson's disability (HDRS, UPDRS and ADL, respectively). In addition, FTT and PPT scores also increased until day 18, with further slight fluctuations around the plateau. Optimal motor performances correlated with Flu concentrations of approximately 60-110 μg/L. Conclusion. Flu (20 mg/day) significantly reduced depression in PD patients while it did not impair their motor performances. Because substantial placebo effects may arise in studies of PD and depression, large, prospective, randomized, placebo-controlled clinical trials are warranted., Uvod/Cilj. Selektivni inhibitori ponovnog preuzimanja serotonina su antidepresivi koji se najčešće koriste u lečenju obolelih od Parkinsonove bolesti (PB). Cilj ovog istraživanja bio je da se proceni uticaj fluoksetina (Flu) na motorne funkcije bolesnika sa PB. Metode. U ovom prospektivnom, kontrolisanom, otvorenom kliničkom ispitivanju, 18 bolesnika sa PB i blagom depresijom [10 ≤ Hamiltonova skala za depresiju (10 ≤ HDRS) ≤ 23)], bez demencije [(25 ≤ Mini mental test (MMSE)] lečeni su primenom Flu. Procenjivana su dejstva kako pojedinačne, tako i ponovljene doze Flu od prvog do osamdesetog dana. Plazma koncentracije Flu i norfluoksetina (NORFlu) korelisane su sa rezultatima odeđenih testova za motorne funkcije: skala za procenu težine PB (UPDRS), test spretnosti kucanja (FTT) i Purdue pegboard Test PPT). Izraženost PD, depresije i demencije procenjivane su korišćenjem standardnih testova [(test dnevnih aktivnosti (ADL), Hoehn.-Yahr. stadijumi (HJ), HDRS, MMSE)]. Rezultati. Ravnotežno stanje za Flu/NORFlu postignuto je 18. dana lečenja. Takav plato u koncentraciji Flu/NORFlu bio je praćen značajnim poboljšanjem rezultata, kako testova za depresiju, tako i za izraženost PB (HDRS, UPDRS i ADL, sledstveno). Dodatno, rezultati FTT-a i PPT-a bili su u porastu do 18. dana, sa blagim fluktuacijama oko platoa. Optimalna motorna postignuća zabeležena su pri koncentraciji Flu od oko 60-110 μg/L. Zaključak. Flu (20 mg/dan) značajno redukuje depresiju kod bolesnika sa PB i ne remeti motorne funkcije. S obzirom na mogući placebo efekat u istraživanjima sa PB i depresijom, neophodna su obimnija, prospektivna, randomizovana, placebo- kontrolisana klinička ispitivanja.",
publisher = "Vojnomedicinska akademija - Institut za naučne informacije, Beograd",
journal = "Vojnosanitetski pregled",
title = "Fluoxetine does not impair motor function in patients with Parkinson's disease: Correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine, Fluoksetin ne remeti motornu funkciju kod bolesnika sa Parkinsonovom bolešću - korelacija raspoloženja i motorne funkcije sa koncentracijom fluoksetina/norfluoksetina u plazmi",
volume = "69",
number = "12",
pages = "1067-1075",
doi = "10.2298/VSP111114028K"
}

Kostić, V., Džoljić, E., Todorović, Z., Mijajlović, M., Svetel, M., Stefanova, E., Dragašević, N., Petrović, I., Milošević, M., Kovačević, I., Miljković, B., Pokrajac, M.,& Prostran, M.. (2012). Fluoxetine does not impair motor function in patients with Parkinson's disease: Correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine. in Vojnosanitetski pregled
Vojnomedicinska akademija - Institut za naučne informacije, Beograd., 69(12), 1067-1075.
https://doi.org/10.2298/VSP111114028K

Kostić V, Džoljić E, Todorović Z, Mijajlović M, Svetel M, Stefanova E, Dragašević N, Petrović I, Milošević M, Kovačević I, Miljković B, Pokrajac M, Prostran M. Fluoxetine does not impair motor function in patients with Parkinson's disease: Correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine. in Vojnosanitetski pregled. 2012;69(12):1067-1075.
doi:10.2298/VSP111114028K .

Kostić, Vladimir, Džoljić, Eleonora, Todorović, Zoran, Mijajlović, Milija, Svetel, Marina, Stefanova, Elka, Dragašević, Nataša, Petrović, Igor, Milošević, Milenko, Kovačević, Ivan, Miljković, Branislava, Pokrajac, Milena, Prostran, Milica, "Fluoxetine does not impair motor function in patients with Parkinson's disease: Correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine" in Vojnosanitetski pregled, 69, no. 12 (2012):1067-1075,
https://doi.org/10.2298/VSP111114028K . .